$2.48
8.84% yesterday
Nasdaq, Jun 26, 10:00 pm CET
ISIN
US23255M1053
Symbol
CYCN
Sector
Industry

Cyclerion Therapeutics,Inc. Share price

$2.48
-0.48 16.23% 1M
-1.70 40.64% 6M
-0.87 25.98% YTD
-1.81 42.20% 1Y
-80.32 97.01% 3Y
-219.52 98.88% 5Y
-247.52 99.01% 10Y
Nasdaq, Closing price Wed, Jun 26 2024
ISIN
US23255M1053
Symbol
CYCN
Sector
Industry

Key figures

Market capitalization $6.72m
Enterprise Value $1.02m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.62
Sales growth (TTM) Sales growth -100.00%
Turnover (TTM) Turnover $0.00
EBIT (operating result TTM) EBIT $-10.37m
Free cash flow (TTM) Free cash flow $-16.90m
Cash position $5.70m
EPS (TTM) EPS $-6.50
Short interest 1.13%
Show more

Is Cyclerion Therapeutics,Inc. a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,947 shares worldwide.

Cyclerion Therapeutics,Inc. Share analysis

Unlock scores for free

Analyst opinions

1 Analyst has issued a forecast Cyclerion Therapeutics,Inc.:

1x Buy
100%

Analyst opinions

1 Analyst has issued a forecast Cyclerion Therapeutics,Inc.:

Buy
100%

Financial data from Cyclerion Therapeutics,Inc.

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
- -
-
100%
- Direct costs - -
-
-
- -
-
-
- Selling and administrative expenses 8.83 8.83
36% 36%
-
- Research and development costs 1.53 1.53
94% 94%
-
-10 -10
73% 73%
-
- Depreciation and amortization - -
-
-
EBIT (operating result) EBIT -10 -10
73% 73%
-
Net profit -16 -16
59% 59%
-

Figures in millions USD.

Don't miss a thing! We will send you all news about the Cyclerion Therapeutics,Inc. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Cyclerion Therapeutics,Inc. Share News

Neutral
GlobeNewsWire
7 months ago
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy –
Neutral
GlobeNewsWire
7 months ago
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders
Neutral
GlobeNewsWire
about one year ago
Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors
More Cyclerion Therapeutics,Inc. News

Company profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Head office United States
CEO Peter Hecht
Employees 1
Founded 2018
Website www.cyclerion.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now